Skip to main content

Advertisement

SpringerLink
Log in

Baseline Neurocognitive Functioning Predicts Viral Load Suppression at 1-Year Follow-Up Among Newly Diagnosed HIV Infected Patients

  • Original Paper
  • Published:
AIDS and Behavior Aims and scope Submit manuscript

Abstract

The current prospective observational study evaluated the impact of baseline neurocognitive impairment on future viral load suppression among antiretroviral medication naive persons newly diagnosed with HIV infection. We used the Montreal Cognitive Assessment (MoCA) score less than 26, to identify patients with neurocognitive deficits. Of the 138 patients enrolled; virologic suppression was seen in 61% of the participants, while 72% of the participants had a MoCA score less than 26 at baseline. Variables significantly associated with low MoCA score included higher age (p < 0.01) and presence of depression (p < 0.01). After adjusting for these variables, MoCA score less than 26 was significantly associated with a higher risk of failing achieve viral load suppression (adjusted OR 2.7; 95% CI 1.09–6.69). Baseline neurocognitive deficit as measured by MoCA was associated with a higher risk for failing to achieve viral load suppression at one-year follow-up.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363(3):257–65.

    Article  CAS  Google Scholar 

  2. INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.

    Article  Google Scholar 

  3. Temprano, ANRS Study Group, Danel C, Moh R, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22.

    Article  Google Scholar 

  4. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815–26.

    Article  CAS  Google Scholar 

  5. Wood E, Kerr T, Marshall BD, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009;338:b1649.

    Article  Google Scholar 

  6. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.

    Article  CAS  Google Scholar 

  7. Reynolds SJ, Makumbi F, Nakigozi G, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS. 2011;25(4):473–7.

    Article  CAS  Google Scholar 

  8. O’Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4 + lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med. 1996;334(7):426–31.

    Article  Google Scholar 

  9. Garcia F, de Lazzari E, Plana M, et al. Long-term CD4 + T-cell response to highly active antiretroviral therapy according to baseline CD4 + T-cell count. J Acquir Immune Defic Syndr. 2004;36(2):702–13.

    Article  Google Scholar 

  10. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2014. HIV Surveillance Supplemental Report 2016;21(No. 4). http://www.cdc.gov/hiv/library/reports/ surveillance/. Published July 2016. Accessed on 2/4/17.

  11. WHO. 90–90–90. An ambitious treatment target to help end the AIDS epidemic; 2014. http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf. Published October 2014. Accessed on 11/4/17.

  12. Chesney MA. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S149–55.

    Article  Google Scholar 

  13. Gross R, Bellamy SL, Chapman J, et al. Managed problem solving for antiretroviral therapy adherence: a randomized trial. JAMA Intern Med. 2013;173(4):300–6.

    Article  Google Scholar 

  14. Koenig LJ, Pals SL, Bush T, et al. Randomized controlled trial of an intervention to prevent adherence failure among HIV-infected patients initiating antiretroviral therapy. Health Psychol. 2008;27(2):159–69.

    Article  Google Scholar 

  15. Garofalo R, Kuhns LM, Hotton A, et al. A Randomized Controlled Trial of Personalized Text Message Reminders to Promote Medication Adherence Among HIV-Positive Adolescents and Young Adults. AIDS Behav. 2016;20(5):1049–59.

    Article  Google Scholar 

  16. Simoni JM, Huh D, Frick PA, et al. Peer support and pager messaging to promote antiretroviral modifying therapy in Seattle: a randomized controlled trial. J Acquir Immune Defic Syndr. 2009;52(4):465–73.

    Article  Google Scholar 

  17. Milam J, Richardson JL, McCutchan A, et al. Effect of a brief antiretroviral adherence intervention delivered by HIV care providers. J Acquir Immune Defic Syndr. 2005;40(3):356–63.

    Article  Google Scholar 

  18. Hasbun R, Eraso J, Ramireddy S, et al. Screening for Neurocognitive Impairment in HIV Individuals: the utility of the Montreal Cognitive Assessment Test. J AIDS Clin Res. 2012;3(10):186.

    Article  Google Scholar 

  19. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Section accessed on May 19, 2017.

  20. Vanheule S, Desmet M, Groenvynck H, et al. The factor structure of the beck depression inventory-II: an evaluation. Assessment. 2008;15(2):177–87.

    Article  Google Scholar 

  21. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.

    Article  Google Scholar 

  22. Brouillette M-J, Mayo N, Fellows LK, et al. A better screening tool for HIV-associated neurocognitive disorders: is it what clinicians need? AIDS. 2015;29(8):895–902.

    Article  Google Scholar 

  23. Jacks A, Wainwright DA, Salazar L, et al. Neurocognitive deficits increase risk of poor retention in care among older adults with newly diagnosed HIV infection. AIDS. 2015;29(13):1711–4.

    Article  Google Scholar 

  24. Ettenhofer ML, Foley J, Castellon SA, et al. Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS. Neurology. 2010;74(15):1217–22.

    Article  Google Scholar 

  25. Tozzi V, Balestra P, Serraino D, et al. Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses. 2005;21(8):706–13.

    Article  Google Scholar 

  26. Coban H, Robertson K, Smurzynski M, et al. Impact of aging on neurocognitive performance in previously antiretroviral-naïve HIV + individuals on their first suppressive regimen. AIDS. 2017;31:1565–71.

    Article  Google Scholar 

  27. Ding Y, Lin H, Shen W, et al. Interaction effects between HIV and aging on selective neurocognitive impairment. J Neuroimmune Pharmacol. 2017;12:661–9.

    Article  Google Scholar 

Download references

Funding

This study was by the Baylor–UT Houston Center for AIDS Research Core Support Grant number AI36211 from the National Institute of Allergy and Infectious Diseases.

Author information

Authors and Affiliations

  1. Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center, 1941 East Road, Houston, TX, 77054, USA

    Lokesh Shahani

  2. Division of Infectious Diseases, University of Texas Health Science Center, Houston, TX, USA

    Lucrecia Salazar & Rodrigo Hasbun

  3. Department of Psychology, University of Houston, Houston, TX, USA

    Steven P. Woods

Authors
  1. Lokesh Shahani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lucrecia Salazar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven P. Woods
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rodrigo Hasbun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lokesh Shahani.

Ethics declarations

Conflicts of interest

Lokesh Shahani, Lucrecia Salazar, Steven P Woods, and Rodrigo Hasbun declare that they have no conflicts of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shahani, L., Salazar, L., Woods, S.P. et al. Baseline Neurocognitive Functioning Predicts Viral Load Suppression at 1-Year Follow-Up Among Newly Diagnosed HIV Infected Patients. AIDS Behav 22, 3209–3213 (2018). https://doi.org/10.1007/s10461-018-2025-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10461-018-2025-5

Keywords

Search

Navigation